Integrative Molecular Phenotyping

KI News

Updated: 41 min 48 sec ago

KI hosted a discussion concerning world health in Almedalen

Thu, 12/07/2018 - 10:12
Only four out of ten Swedes are aware of the 17 global objectives that the UN set for sustainable development by 2030. An increase in awareness of these objectives and why they are necessary, is a first step in increasing commitment across parts of society. This was noted at KI's seminar in Almedalen. Do you know the world’s PIN code? It is 1114. The code was an educational device created by former KI professor Hans Rosling, with the idea being that the code would symbolise the geographical distribution of the world’s population. Approximately one billion people live in America, one billion in Europe, one billion in Africa and four billion in Asia: 1114. But the population is still increasing in Africa and Asia. By 2100, the pin code is expected to read as 1145 instead. The majority of these people will be between 15 and 74 years old.  Knowing what the world looks like is important for health improvement work. This was the opening message at Tuesday’s KI seminar in Almedalen. In some places, health has improved dramatically in the past few decades. For example, the average life span today is as high as 72 years. Many no longer die from infections such as HIV, malaria or pregnancy and birth-related ailments, and instead die from non-infectious diseases which affect people far later on in life. Although large parts of the world have improved considerably, others have changed very little. In countries with lower incomes, women still give birth to five children on average, and child and mother morality is very high. A vision for a better world “Without a clear map of the world we cannot work on these important issues,” said Tobias Alfvén, researcher for Public Health Sciences at KI. He and his colleague Helena Nordenstedt introduced the seminar, which had the title “Who takes responsibility for world health”. The aim was to discuss how the 17 objectives of the 2030 Agenda, a vision for a better world, as assumed in 2015 by the United Nations General Assembly, should be achieved. And the challenges facing the future naturally contain a range of clean health issues such as antibiotic resistance and new infections, among other problems.  “Climate change deems large areas inhabitable and war and nationalism leads to poverty and depletion of resources. Ten years ago, Syria was a middle-income country with good health and medical care accessible for the vast majority, however today it is a low-income country where child mortality is on the rise. Poverty is perhaps the most important objective to combat, if we are to progress further”, said Tobias Alfvén.   Unexpected alliances The final objective concerns working together in order to achieve the objectives. And it is going to be crucial, according to Ole Petter Ottersen, President of KI.  “According to the declaration, responsibility rests not only with the UN and governing politicians, but also with civil society, entrepreneurs and indeed everyone else. And this is what is so fantastic about the 2030 Agenda – that it gives us all responsibility for doing something. However giving everyone responsibility also risks resulting in nobody taking responsibility”, he said. In the subsequent panel discussion, participants were invited to discuss how unexpected alliances could increase opportunities for creating a sustainable world. Ingrid Petersson, Chairman of the government’s 2030 Agenda delegation, said that this requires both profound expertise, a horizontal thinking and a holistic approach. She wants to see increased partnership within higher education. “Humanities, social science, natural science, technology and medicine: United for a better world!” she said. Highlighting the economic aspects of health problems could be a way of getting politicians to engage in these issues according to Sofia Arkelsten, Moderate MP.  “It can be a matter of addressing finance ministers and prime ministers and also discussing the economic gains, instead of talking with health ministers”, she said.  Niklas Adalberth, founder of Klarna and the Norrsken foundation, said that economic growth is necessary in order to counteract poverty.  “Today, many entrepreneurs invest in the technology industry. However, it would be great if we could persuade more of these enthusiasts and risk takers to focus on technologies that can solve real societal problems, instead of developing a new image sharing app”, he said.  As an example, he mentioned Matsmart, an app that reduces food wastage. “By turning community entrepreneurs into tomorrow's rock stars, we are taking a step in the right direction”, he said.  Future markets The opportunity to create future markets could be a way of motivating companies to invest in long-term projects in low-income countries, which simultaneously leads to health benefits. One example was provided by Suzanne Håkansson, manager of social affairs at AstraZeneca. The company has worked in Kenya together with an American aid organisation which focuses on HIV and Aids and has set-up clinics for simultaneous blood pressure measurements and HIV tests.  She explained that many do not come to HIV testing because the disease is very stigmatised, but they do come to have their blood pressure measured, and you can take the opportunity to take an HIV test as well.   Stefan Swartling Peterson, Chief of Health at UNICEF, New York, also emphasised that these issues are not limited to the field of healthcare and medicine.  “Health is about food, water, homes and schools, and to a small, small extent about healthcare. We must spread this message”, he said. Create a movement Pernilla Bergström, Project Manager of the 2030 Agenda of the United Nations Association of Sweden agreed that the dissemination of knowledge is important.  “It does not matter how much we stand here and talk about responsibility and ownership if people are not aware that the global objectives exist. Today, approximately four out of ten Swedish people are aware of the objectives. We want to create a movement to increase awareness of the objectives, why they exist and why they are important, even for us in Sweden. But also to discuss the consequences of not working with the objectives, as well as what everybody can do within their organisations”, she said. When asked who their ideal partner would be for working on the global objectives, researchers, the food industry and the world’s private pension capital were all brought up. For KI’s President Ole Petter Ottersen, it is the students. “They are future leaders and it is our mission to make sure they are prepared”. The seminar’s moderator was Carl Johan Sundberg, Professor at the Department of Physiology and Pharmacology at Karolinska Institutet.

Combination of blood test and imaging improves detection of prostate cancer

Mon, 09/07/2018 - 12:00
New research from Karolinska Institutet shows that the blood test Stockholm3 together with magnetic resonance imaging and targeted prostate biopsies may lead to a significant decrease in the number of biopsy procedures and diagnoses of harmless disease. The study is published in European Urology. The study compares traditional detection of prostate cancer with a novel practice using a blood test, the Stockholm3 test, in combination with magnetic resonance imaging (MRI) and targeted prostate biopsies. More men get a correct diagnosis and treatment The results show that the suggested diagnostic strategy decreased the number of biopsy procedures with 38 per cent and the number of men getting a diagnose with harmless disease by 42 per cent. At the same time, the number of men diagnosed with potentially harmful cancer increased with 10 per cent. The study was performed in collaboration with Swedish (Stockholm) and Norwegian (Oslo, Tönsberg) urology practices and includes 532 men. ”We show that a combination of the Stockholm3 test and targeted prostate biopsies might increase the number of men with potentially dangerous disease that get a diagnosis. At the same time, we can spare many men from unnecessary prostate biopsies. This means that more men get a correct diagnosis and treatment, and that we can decrease unnecessary discomfort and risks, says Tobias Nordström, researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet and urologist at Danderyd Hospital. Need for improved diagnosis In the European Union, prostate cancer is the most frequently diagnosed cancer among men, with around 365,000 new cases yearly and 77,000 men dying from prostate cancer. Current practice includes a so called PSA test and systematic prostate biopsies where 10-12 samples are taken from the prostate. The PSA test has been controversial because it only poorly differentiates between lethal and harmless prostate cancer. The Stockholm3 test is an alternative test method that combines five biomarkers, over 100 genetic markers and clinical data such as age, previous biopsies and family history of prostate cancer to better assess the risk of potentially harmful prostate cancer. “The current study confirms our previous findings showing the value of the Stockholm3 test as part of the diagnosis of prostate cancer. Studies of this type have been requested by the National Board of Health and Welfare in Sweden,” says Tobias Nordström. The research was funded by the Swedish Cancer Society, the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, The Strategic Research Programme in Cancer at Karolinska Instituet (StratCan), Karolinska Institutet och The Swedish e-Science Research Centre (SeRC). The Stockholm3 test was developed by researchers at Karolinska Institutet in collaboration with Thermo Fisher Scientific. Professor Henrik Grönberg, lead author of this study, has patent applications for the Stockholm3 test licensed to Thermo Fisher Scientific, and might receive royalties from sales related to these patents. Co-author Martin Eklund is named on some of these patent applications. Publication Prostate cancer diagnostics using a combination of the Stockholm3 blood-test and multiparametric magnetic resonance imaging.  Henrik Grönberg, Martin Eklund, Wolfgang Picker, Markus Aly, Fredrik Jäderling, Jan Adolfsson, Martin Landquist, Erik Skaaheim Haug, Peter Ström, Stefan Carlsson, Tobias Nordström. European Urology, online 9 july 2018.

Higher risk of heart defects in babies of mothers with type 1 diabetes

Thu, 05/07/2018 - 06:00
Pregnant women with type 1 diabetes run a higher risk of having babies with heart defects, especially women with high blood glucose levels during early pregnancy, a study from Karolinska Institutet and the Sahlgrenska Academy in Sweden published in The BMJ shows. It has long been known that patients with type 1 diabetes are at increased risk of complications. A new study now shows that pregnant women with type 1 diabetes are at a higher risk of having babies with heart defects. “This confirms previous findings that there is a higher risk of birth defects, primarily of the heart,” says Professor Jonas F. Ludvigsson at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and consultant at the Paediatric Clinic at Örebro University Hospital. “The risk of birth defects is especially sensitive to factors during early pregnancy, and here blood glucose plays a vital part.” A clear correlation The study demonstrates a clear correlation between elevated levels of blood glucose (HbA1c) in the mother and the risk of heart defects in her baby. However, even those women who followed the current guidelines had a higher, albeit still small, risk of heart defects. The results show that 3.3 per cent of pregnant women with type 1 diabetes and blood glucose levels within the recommended span gave birth to a baby with a heart defect. The corresponding figure for women without diabetes was 1.5 per cent. Pregnant women with type 1 diabetes who had very high blood glucose levels (an HbA1c reading of 9.1 per cent or higher) were at much greater risk. “Here, the risk of the baby having a heart defect was as much as 10.1 per cent – or one in every ten babies,” says Professor Ludvigsson. “The reason why the risk of deformity can be linked to blood glucose levels in early pregnancy is that it is then that the fetus’s organs develop. Also, many women aren’t aware that they’re pregnant during the first few months.” This, he stresses, is why women must know about the dangers before trying to have children. Opportunity to influence the risk “There’s an opportunity here for women to influence the risk of their baby developing a heart defect by keeping their blood glucose levels low. Yet we as doctors also know that many pregnant women struggle valiantly to keep their blood glucose down, as it is no easy task. The potential benefit of intensified insulin treatment to reduce the risk of heart defects should also be weighed against possible risks with hypoglycaemia in the mother and foetus,” says Professor Ludvigsson. The study was done by cross-referencing the National Diabetes Register with the National Patient Register and the Medical Birth Registry, and comparing 2,458 living newborns of mothers with type 1 diabetes with 1,159,865 babies of mothers without diabetes. Since this is an observational study no definitive conclusions can be drawn regarding causality. The researchers are now planning to make further investigations in the field. The study was financed with grants from the Swedish Diabetes Association, the Strategic Research Area in Epidemiology (SfoEpi) at Karolinska Institutet, the Swedish Research Council and Stockholm County Council. Publication  “Periconceptional glycemic control in type 1 diabetes and the risk of major birth defects: population based cohort study in Sweden” Jonas F. Ludvigsson, Martin Neovius, Jonas Söderling, Soffia Gudbjörnsdottir, Ann-Marie Svensson, Stefan Franzén, Olof Stephansson, Björn Pasternak The BMJ, online 5 July 2018, doi: 10.1136/bmj.k2638

Solvents and smoking linked to increased risk of MS

Wed, 04/07/2018 - 06:00
People who carry genes that make them more susceptible to developing multiple sclerosis (MS) are at much greater risk of developing the disease if they have been exposed to paint, varnish and other solvents, according to a new study from Karolinska Institutet published in the journal Neurology. If they have also been smokers, the risk of developing MS is multiplied. The study shows that people who have been exposed to paint or other solvents are 50 per cent more likely to develop MS than people with no exposure. People with exposure to solvents who also carry certain gene variants that make them more susceptible to MS are ten times as likely to develop the disease as people with no solvent exposure who do not carry the MS genes. Different risk factors People with exposure to solvents who carry the MS genes and in addition to that have been smokers are as much as 30 times more likely to develop MS, compared to those who have never smoked or been exposed to solvents and who do not have the genetic risk factors. How these different factors interact to create a much greater risk than they do on their own is not yet known. ”It’s possible that exposure to solvents and smoking may both involve lung inflammation and irritation that leads to an immune reaction in the lungs,” says lead author Anna Karin Hedström at the Institute of Environmental Medicine and the Department of Clinical Neuroscience, Karolinska Institutet. “How this cocktail of MS genes, organic solvents and smoking contributes so significantly to MS risk warrants investigation,” comments Gabriele C. DeLuca, MD, PhD, of the University of Oxford in the United Kingdom, in an accompanying editorial. “In the meantime, avoiding cigarette smoke and unnecessary exposure to organic solvents, particularly in combination with each other, would seem reasonable lifestyle changes people can take to reduce the risk of MS, especially in people with a family history of the disease.” Study included 5,000 people The study included more than 2,000 people who had recently been diagnosed with MS in Sweden and almost 3,000 people of the same age and sex without MS. Blood tests were used to determine which human leukocyte antigen gene variants the participants had. They were also asked about previous exposure to organic solvents, painting products or varnish and whether they had ever been a smoker. One limitation of the study is that it is possible that the participants may not have remembered correctly. Moreover, since it is an observational study no definitive conclusions can be drawn regarding causality. The study was funded by the Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, Knut and Alice Wallenberg Foundation, AFA Insurance, Swedish Brain Foundation and Neuro Sweden. This news article is based on a press release from the American Academy of Neurology. Publication ”Organic solvents and MS susceptibility; interaction with MS risk HLA genes” Anna Karin Hedström, Ola Hössjer, Michail Katsoulis, Ingrid Kockum, Tomas Olsson, Lars Alfredsson. Neurology, online 3 July 2018, doi: 10.1212/WNL.0000000000005906

Molecular brake on human cell division prevents cancer

Thu, 28/06/2018 - 17:00
Researchers at Karolinska Institutet and the University of Sussex have discovered that the process of copying DNA generates a brake signal that stalls cell division. This molecular brake ensures that the cell has two complete copies of DNA before it divides and thus prevents DNA damage and cancer development. The study is published in the scientific journal Molecular Cell. One of biology’s great mysteries is how a single fertilised egg can generate millions of cells that together make up a human body, while simultaneously restricting growth to prevent lethal diseases such as cancer. This process is strictly regulated by our DNA, the genetic cookbook carried by each single cell in our body. Before a cell divides and generates two new daughter cells, it has to copy its DNA. How cells decide when to divide is a long-standing question in science. Now, an international collaboration between Karolinska Institutet, Sweden, and the University of Sussex, England, led to the discovery of a built-in molecular brake on human cell division. The researchers revealed that the process of copying DNA generates a brake signal that stalls cell proliferation. This mechanism ensures that the cell has two complete copies of DNA before it divides and that all cells in a human contain similar genomes. “By creating cells that cannot copy their DNA and by following protein activities over time in single cells, we found that DNA replication blocks the enzymes that trigger cell division. Immediately after DNA replication is completed, the machinery that starts cell division is activated. This fundamental mechanism contributes to determining when human cells will divide,” says Arne Lindqvist, senior researcher at the Department of Cell and Molecular Biology at Karolinska Institutet who led the study. The researchers also show that the molecular brake ensures that the amount of DNA damage is minimised. When the brake is not functional, the cell divides before it is ready resulting in large amounts of DNA damage. “Our study highlights the dangerous consequences of hasty cell division and provides important clues on how cells might gain DNA mutations that ultimately give rise to cancer,” says lead author Bennie Lemmens, postdoctoral researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet. The research was supported by the Wenner-Gren Foundation, the Swedish Research Council and the Swedish Cancer Society, among others. Publication “DNA replication determines timing of mitosis by restricting CDK1 and PLK1 activation” Bennie Lemmens, Nadia Hegarat, Karen Akopyan, Joan Sala-Gaston, Jiri Bartek, Helfrid Hochegger, Arne Lindqvist. Molecular Cell, online 28 June 2018, doi: 10.1016/j.molcel.2018.05.026

Seven researchers responsible for scientific misconduct in Macchiarini case

Mon, 25/06/2018 - 13:44
On 25 June, the President of Karolinska Institutet made the decision to find seven researchers responsible for scientific misconduct in research. The case concerns six articles published in the scientific journals The Lancet, Biomaterials, The Journal of Biomedical Materials Research and Thoracic Surgery Clinics. Paolo Macchiarini is one of the main authors of the articles. The research reported in the articles relates to the transplantation of synthetic tracheal prostheses and describes the clinical course of treatment of three patients who were transplanted at Karolinska University Hospital 2011–2013. According to the President's decision, an additional 31 authors are blameworthy for their contributions to the articles, however not responsible for scientific misconduct. Another five authors are cleared of blame and of responsibility for scientific misconduct. Karolinska Institutet is requesting that the six articles be retracted without undue delay. Today's decision was made following a new investigation of the six articles, and overturns the decision made on 28 August 2015 by the President at the time. The case was reopened in February 2016. The new investigation points to serious inaccuracies and misleading information in the reviewed articles. The articles contain fabricated and distorted descriptions of the patients’ conditions before and after the operations. Justification is lacking for treatment of the patients on the grounds of so-called vital indication (when a given treatment is the last resort for survival), and one misses reference to relevant animal experiments which must precede human studies that involve unproven methods. Furthermore, ethical approvals are lacking, as are appropriate informed consents. “This decision has been made after careful investigations in a case that has had major impact on Karolinska Institutet, on the scientific community at large, and on public confidence in medical research. In particular, the case has had tragic consequences for patients and their relatives, for which I am deeply sorry. Karolinska Institutet will now continue to implement the measures that are necessary to prevent something like this from happening again,” says Ole Petter Ottersen, President of Karolinska Institutet. One of the authors that was found responsible for misconduct was among those who blew the whistle on Macchiarini in 2014. “The investigation points to inaccuracies for which Paolo Macchiarini is ultimately responsible but for which several of the co-authors also bear responsibility. The four whistle blowers are to be commended for their action in this case that has contributed to the investigation. However, it is KI:s firm opinion that a whistle blower who has participated in a scientific study and also as author of a scientific article, despite reporting, cannot be freed from blame or absolved from responsibility”, says Ole Petter Ottersen. According to Chapter 1, § 16 of the Higher Education Ordinance, a university that becomes aware of suspected scientific misconduct at said institution is obliged to investigate. In the course of an ongoing investigation, the higher education institution may solicit the opinion of the Expert group for misconduct in research at the Central Ethical Review Board, CEPN. According to KI procedure, suspected scientific misconduct is to be reported to the president of the university, and the president shall initiate an investigation and make a decision in the case. The university where the research was conducted has an obligation to investigate suspected scientific misconduct even if all the involved researchers are not employed at or affiliated to that university. Today's decision differs from the report of the Expert group for misconduct in research at the Central Ethical Review Board, CEPN, who considers all authors responsible for scientific misconduct. Karolinska Institutet's investigation has examined the responsibility of each individual author (a total of 43 researchers). Only a few of the authors are currently employed at or affiliated to Karolinska Institutet. The decision made on 25 June 2018 relates to the following articles: - Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study, Lancet 2011; 378(9808): 1997–2004, - Engineered whole organs and complex tissues, Lancet 2012; 379(9819): 943–952, - Verification of cell viability in bioengineered tissues and organs before clinical transplantation, Biomaterials 2013; 34(16): 4057–4067, - Are synthetic scaffolds suitable for the development of clinical tissue-engineered tubular organs? Journal of Biomedical Material Research 2014; 102(7): 2427–2447, - Airway transplantation, Thoracic Surgery Clinics 2014; 24(1): 97–106, - Biomechanical and biocompatibility characteristics of electrospun polymeric tracheal scaffolds, Biomaterials 2014; 35(20): 5307–5315.

KI launches global alumni chapter in Vietnam

Thu, 21/06/2018 - 11:18
Một hai ba uống! (One two three, cheers!) filled the room as joyful KI alumni raised glasses to sing a celebratory song in unison. Gathered in the idyllic village of Ninh Bình KI:s alumni in Vietnam united to celebrate the launch of the KI Alumni Vietnam global chapter on Saturday 16 June 2018. – The official launch of the KI Alumni chapter is important for everyone in Vietnam. The establishment of the chapter confirms that we are important to the university, and provides greater opportunity to maintain our connection with KI, says Nguyễn Thị Thanh Hương, ambassador of KI Alumni Vietnam Chapter. A short dinner program began with a video greeting sent by KI President Ole Petter Ottersen. – This is a major step forward for KI and for our profile in southeast Asia. You, our alumni, are our most important ambassadors. You contribute to our vision, which is to improve human health, not only in Sweden, but globally. Sida-funded sandwich model Ingeborg van der Ploeg, or ”Chị In” as she is affectionately known, has been a key facilitator between KI and Vietnam as a coordinator for the Sida-funded sandwich model PhD program. Ingeborg has followed the progress of more than twenty alumni including exchange students since 2000. KI has had collaborations with Vietnam for several decades, and today has several ongoing projects including the collaborative Stint-funded Trac (Teaching and Research Academic Collaboration) project, and Edushare, a capacity-building project led by Tartu University in Estonia. Professor Marianne Schultzberg, Dean of Doctoral Education, is the chair of the Trac owner group. – The establishment of the KI Alumni Vietnam global chapter will add great value to Trac and similar projects by facilitating a consistent network through which further collaboration can arise – both with KI and between our alumni, remarks Marianne Schultzberg. The KI alumni in Vietnam hope that the establishment of the chapter will foster the KI spirit in Vietnam, bring about better contact between KI and the alumni, and increase opportunities regarding teaching, and clinical and research exchange in both directions.

Lennart Nilsson Award 2018 is awarded to Thomas Deerinck

Wed, 20/06/2018 - 17:26
Bio-artist and scientist Thomas Deerinck wins the 2018 Lennart Nilsson Award. He gets the prize for developing novel microscopy techniques and methods to improve the ability to obtain information from biological specimens. Thomas Deerinck is a research scientist, technical specialist and bio-artist at the National Center for Microscopy and Imaging Reseach (NCMIR) and the Center for Research on Biological Systems at the University of California, San Diego. Over the past four decades he has developed novel techniques and methods to improve our ability to obtain information from biological specimens using many types of microscopes. He has made many important contributions to the field of bioimaging, including key work on developing chemical, molecular and genetic tagging methods for studying cells and tissues by both light and electron microscopy. Thomas Deerincks latest work is focused on improving serial block-face scanning electron microscopy; a method that is revolutionizing automated 3D imaging of cells and tissues at nanometer-scale resolution. He not only developed the now gold-standard protocol for preparing samples for this imaging technique, but also just recently co-developed a method to greatly extend the resolution and usefulness of this approach in the field of biomedical research. Thomas is married to the artist Karla Renshaw, who taught him to bring an artistic eye common to nature photography to scientific imaging with microscopes. The resulting images of even common everyday objects are turned from the invisible into beautiful works of art, and have appeared not only on the cover of numerous top tier scientific journals, but also in many non-scientific magazines, periodicals, documentaries as well as public art exhibitions.  

Mechanism controlling multiple sclerosis risk identified

Tue, 19/06/2018 - 11:01
While the DNA sequence remains the same throughout a person’s life, the expression of the encoded genes may change with time and contribute to disease development in genetically predisposed individuals. Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism. The study is published in Nature Communications. Multiple sclerosis is a chronic inflammatory disease of the central nervous system, affecting people at a relatively young age. Most are between 20 and 40 years old when they get the first symptoms, in the form of, for example numbness in the arms and legs, visual impairment and dizziness, but also fatigue and depression. The symptoms are caused by an inflammation in the brain and the spinal cord that breaks down the myelin sheath protecting the nerves, thus damaging the axons. Currently there is no cure for MS, but the disease activity can often be halted through medication. Strongest risk factor Already over 40 years ago it was discovered that genetic variation in the so-called HLA region is the strongest risk factor for developing disease. HLA encodes molecules that are involved in the immune system. However, the specific genes and molecular mechanisms behind the emergence of the disease are not fully established. By using molecular analyses and combining several studies (so-called meta-analysis), including around 14,000 patients with MS and a control group of more than 170,000 healthy individuals, researchers at Karolinska Institutet found that people with the major risk variant HLA-DRB1*15:01 have an increased expression of the HLA-DRB1 gene, thus increasing the risk for the disease. The researchers further discovered a so-called epigenetic regulation of HLA expression as the mechanism mediating this effect. “We show for the first time that epigenetic mechanisms can cause the disease. In addition, we can connect this mechanism to the genetic variant with the strongest risk for developing MS,” says Maja Jagodic, researcher at the Department of Clinical Neuroscience at Karolinska Institutet and one of the authors of the article. Protective variant The researchers also discovered a new HLA gene variant, rs9267649, which reduces the risk of developing MS. This protective variant decreases the HLA-DRB1 gene expression – through the same epigenetic regulation mechanism – thus reducing the risk for MS. The results open new avenues for potential alternative treatments based on specific epigenetic modulation, i.e. to prevent gene expression artificially. This gives hope for people with MS, as well as other autoimmune diseases. “Almost all autoimmune diseases are associated with HLA,” says Lara Kular, co-author and researcher at the same department. The study was carried out through an international collaboration with researchers in the US, Germany, Norway, Denmark, and Iceland (the deCode company). Financing has been granted through funding from, among others, the Swedish Research Council, Neuro, the Swedish Brain Foundation, the European MS Foundation, Petrus and Augusta Hedlund Foundation, AFA Insurance, Knut and Alice Wallenberg Foundation, Stockholm County Council, and AstraZeneca. Several of the researchers are employed by deCode genetics/Amgen Inc. For more information, see the scientific article. Publication ”DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis” Lara Kular, Yun Liu, Sabrina Ruhrmann, Galina Zheleznyakova, Francesco Marabita, David Gomez-Cabrero, Tojo James, Ewoud Ewing, Magdalena Lindén, Bartosz Górnikiewicz, Shahin Aeinehband, Pernilla Stridh, Jenny Link, Till F. M. Andlauer, Christiane Gasperi, Heinz Wiendl, Frauke Zipp, Ralf Gold, Björn Tackenberg, Frank Weber, Bernhard Hemmer, Konstantin Strauch, Stefanie Heilmann-Heimbach, Rajesh Rawal, Ulf Schminke, Carsten O. Schmidt, Tim Kacprowski, Andre Franke, Matthias Laudes, Alexander T. Dilthey, Elisabeth G. Celius, Helle B. Søndergaard, Jesper Tegnér, Hanne F. Harbo, Annette B. Oturai, Sigurgeir Olafsson, Hannes P. Eggertsson, Bjarni V. Halldorsson, Haukur Hjaltason, Elias Olafsson, Ingileif Jonsdottir, Kari Stefansson, Tomas Olsson, Fredrik Piehl, Tomas J. Ekström, Ingrid Kockum, Andrew P. Feinberg, and Maja Jagodic Nature Communications, online 19 June 2018, doi: 10.1038/s41467-018-04732-5

Russian research centre delegation visits KI

Sat, 16/06/2018 - 11:36
Thursday 14 June saw a visit to Karolinska Institutet by a Russian delegation from the Almazov National Medical Research Centre. The purpose of the visit was to discuss ongoing and strengthened collaboration. The Almazov National Medical Research Centre is a medical institute in St. Petersburg, primarily specialising in cardiology, cardiovascular surgery, haematology and endocrinology. A number of researchers at the Russian research centre have defended their theses at Karolinska Institutet under the supervision of Göran Hansson, Per Eriksson, Ulf Hedin, Thomas Sejersen, Olle Söder, Boris Zhivotovsky and Anna Kostareva, among others. The latter is an associate at Karolinska Institutet’s Department of Women's and Children's Health and is at the same time head of the Institute of Molecular Biology and Genetics at Almazov National Medical Research Centre in Russia. International challenges require collaboration The Russian research centre, which recently achieved the status of national centre, lists Karolinska Institutet as its foremost collaboration partner. “The challenges currently facing healthcare systems and the medical environments in various countries are not national, but international. This demands joint efforts on the part of research institutes and universities in different countries to identify new solutions and innovative methods. Our almost 20 years of collaboration with Karolinska Institutet has so far proved successful and I believe that the current stage of our relationship is the most important for both parties,” says Professor Evgeny Shlyakhto, Director General of the Almazov National Medical Research Centre and President of the Russian Society of Cardiology. Important collaboration for KI The delegation was received in Aula Medica in the presence of Karolinska Institutet’s President Ole Petter Ottersen, together with researchers who in various ways participate in the Russian collaboration. “Our collaboration with the Almazov Medical Centre is important to KI as it is Russia’s leading institute for cardiological research. Much of the research collaboration takes place with the Department of Women's and Children's Health here at KI, something that is well aligned with the goals of Agenda 2030, both with regard to good health and wellbeing, and gender equality,” says President Ole Petter Ottersen.

No link found between oral antifungal drug and stillbirth

Wed, 13/06/2018 - 09:56
New research led from Karolinska Institutet does not support a suggested link between treatment with the oral antifungal drug fluconazole during pregnancy and an increased risk of stillbirth. The study is published in the prestigious medical journal JAMA. Vaginal candidiasis is common in pregnancy. Intravaginal formulations of topical antifungal drugs are first-line treatment for the infection, but oral antifungal drugs – typically fluconazole – are used in cases with severe symptoms, recurrent candidiasis episodes, or when topical treatment has failed. Although use of oral fluconazole during pregnancy is generally discouraged, between 0.5 and 4 per cent of pregnant women use this drug anyway; with the lower numbers representative of the Nordic countries and the higher numbers reported from the United States. “In a study published in JAMA 2016, we reported that fluconazole use in pregnancy was linked to an increased risk of spontaneous abortion, and our results suggested that the drug might also be associated with stillbirth. There are concerns based on animal data that oral fluconazole use in pregnancy may lead to fetal death. Given this concern and the paucity of studies in humans, we wanted to investigate the issue further,” says Björn Pasternak, associate professor at Karolinska Institiutet’s Department of Medicine in Solna who led the new study. Swedish and Norwegian register data  The researchers at Karolinska Institutet have now conducted an independent study in collaboration with the Norwegian Institute of Public Health to investigate if fluconazole use in pregnancy is associated with stillbirth and neonatal death. More than 10 000 women using fluconazole during pregnancy were identified using nationwide Swedish and Norwegian register data and compared to 100 000 women who did not use the drug. The study, published in JAMA, shows that use of fluconazole was not associated with increased risk of stillbirth or neonatal death, and the results were similar for different drug doses. “The findings are reassuring but need to be interpreted considering other pregnancy safety issues with fluconazole, such as malformations, before recommendations to guide clinical decisions are made,” concludes Dr Pasternak. The study was supported by the Thrasher Research Fund, the Magnus Bergvall Foundation, and the Karolinska Institutet Research Foundation. Björn Pasternak and Olof Stephansson were also supported by the Strategic Research Area Epidemiology program at Karolinska Institutet. Publication “Oral fluconazole in pregnancy and risk of stillbirth and neonatal death” Björn Pasternak, Viktor Wintzell, Kari Furu, Anders Engeland, Martin Neovius, Olof Stephansson JAMA, online 12 June 2018, doi: 10.1001/jama.2018.6237

Genome-editing tool could increase cancer risk

Mon, 11/06/2018 - 17:01
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study from Karolinska Institutet and the University of Helsinki published in Nature Medicine. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies. CRISPR-Cas9 is a molecular machine first discovered in bacteria that can be programmed to go to an exact place in the genome, where it cuts the DNA. These precise ‘molecular scissors’ can be used to correct faulty pieces of DNA and are currently being used in clinical trials for cancer immunotherapy in the US and China. New trials are expected to be launched soon so as to treat inherited blood disorders such as sickle cell anaemia. Activates the p53 protein Two independent articles published in the journal Nature Medicine now report that therapeutic application of the genome-editing tool may, in fact, increase the risk of cancer. In one of the studies, scientists from Karolinska Institutet and the University of Helsinki report that use of CRISPR-Cas9 in human cells in a laboratory setting can activate a protein known as p53, which acts as a cell’s ‘first aid kit’ for DNA breaks. Once active, p53 reduces the efficiency of CRISPR-Cas9 gene editing. Thus, cells that do not have p53 or are unable to activate it show better gene editing. Unfortunately, however, lack of p53 is also known to contribute to making cells grow uncontrollably and become cancerous. “By picking cells that have successfully repaired the damaged gene we intended to fix, we might inadvertently also pick cells without functional p53”, says Dr Emma Haapaniemi, researcher at the Department of Medicine, Huddinge, Karolinska Institutet and co-first author of the study. “If transplanted into a patient, as in gene therapy for inherited diseases, such cells could give rise to cancer, raising concerns for the safety of CRISPR-based gene therapies.” A powerful tool “CRISPR-Cas9 is a powerful tool with staggering therapeutic potential”, adds Dr Bernhard Schmierer, researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, and Head of the High Throughput Genome Engineering Facility of Science for Life Laboratory (SciLifeLab), who co-supervised the study. “Like all medical treatments however, CRISPR-Cas9-based therapies might have side effects, which the patients and caregivers should be aware of. Our study suggests that future work on the mechanisms that trigger p53 in response to CRISPR-Cas9 will be critical in improving the safety of CRISPR-Cas9-based therapies.” Parts of the study were carried out at the Swedish National Genomics Infrastructure, funded by SciLifeLab. The Knut and Alice Wallenberg Foundation, the Swedish Cancer Society, the Swedish Childhood Cancer Fund and the Academy of Finland supported the research. Publication “CRISPR/Cas9-genome editing induces a p53-mediated DNA damage response” Emma Haapaniemi, Sandeep Botla, Jenna Persson, Bernhard Schmierer and Jussi Taipale Nature Medicine, online 11 June 2018, doi: 10.1038/s41591-018-0049-z

Immune system does not recover despite cured hepatitis C infection

Mon, 11/06/2018 - 11:01
Changes to the immune system remain many years after a hepatitis C infection heals, a new study by researchers at Karolinska Institutet and Hannover Medical School shows. The findings, presented in Nature Communications, increases understanding about chronic infection and the way it regulates and impacts composition of the immune system. Infection with hepatitis C virus (HCV) turns almost always chronic and poses a major health problem around the world. The infection can lead to cirrhosis and cancer of the liver when the immune system fails to fight the virus. Eventually the immune system becomes exhausted. Since a couple of years, however, most patients with HCV can now be cured in a matter of a few weeks with revolutionary new medications. New measurement method used The current study included 40 patients with chronic HCV infection whom researchers followed before, during and after treatment with these new medications to investigate impact on the composition and diversity of the immune system. Diversity is vital to the ability of the immune system to fight infections. Of particular importance are natural killer cells (NK), a type of white blood cells. The researchers used flow cytometry and a new measurement method to derive the composition of the immune system, as well as the appearance of NK cells and their function in the blood. “Researchers in the field previously focused on analysing individual components but were unable to draw any comprehensive conclusions,” says Niklas Björkström, physician and associate professor at the Department of Medicine, Huddinge, Karolinska Institutet, who led the study. “The immune system is extraordinarily complex, incorporating a large number of interacting parts. We adapted new methods in order to assess and analyse that complexity in a fresh manner.” The immune system was affected The results showed that the overall composition of the immune system was affected by the chronic infection, with significantly reduced diversity among the NK cells. Many of the changes remained long after the virus had been eliminated by means of medication. Researchers have not yet determined the long-term implications but are currently exploring whether patients have a harder time fighting future infection. “One strength of our study is that we monitored patients for more than two years following elimination of the virus,” Benedikt Strunz, physician and doctoral student at the same department. “To the best of our knowledge, nobody has ever monitored over such a long term like this before.” Nevertheless, a number of questions are outstanding. Researchers would like to investigate consequences for a good deal longer than two years, as well as identify strategies for rejuvenating the immune system and increasing its diversity. The study was financed by the Swedish Research Council, Swedish Cancer Society, Strategic Research Foundation, Swedish Foundation for Medical Research, Radiumhemmet Research Foundation, Knut and Alice Wallenberg Foundation, NovoNordisk Foundation, Åke Wiberg Foundation, Centre for Innovative Medicine at Karolinska Institutet, Stockholm County Council, Karolinska Institutet, International Research Training Group with support by the German Research Foundation, Centre Research Grants, 900 with support of DFG, German Centre for Infection Research and German Liver Foundation. Publication ”Chronic hepatitis C virus infection irreversibly impacts human NK cell repertoire diversity” Benedikt Strunz, Julia Hengst, Katja Deterding, Michael P. Manns, Markus Cornberg, Hans-Gustaf Ljunggren, Heiner Wedemeyer, and Niklas K. Björkström. Nature Communications, online 11 June, 2018, doi: 10.1038/s41467-018-04685-9

Makerere University and KI strengthen partnership

Fri, 08/06/2018 - 15:05
A delegation from Uganda’s Makerere University visited Karolinska Institutet on 7-8 June for talks on strengthening the collaborative partnership between the two universities.   The delegation, which was led by Makerere University’s vice-chancellor Professor Barnabas Nawangwe, met the Karolinska Institutet (KI) management to discuss the long-standing collaboration between the two institutions. The partnership, which began back in 2003  with the first memorandum of understanding, enables doctoral students to obtain a joint PhD from both universities. “The partnership with Makerere University is one of our most important and far-reaching international partnerships, including as it does student and teacher exchange, joint doctoral education and research collaboration,” says KI president Ole Petter Ottersen. Discussed research collaboration During the visit, which included a tour of KI’s new Neo and Biomedicum research facilities, discussions were held on common research interests surrounding non-communicable diseases, such as cardiovascular diseases, cancer, diabetes and chronic respiratory infections that can lead premature death. Apart for the human suffering they cause, they are also a major global economic burden and most countries are doing all they can to develop their healthcare systems to prevent and treat the diseases. KI and Makerere University are now working on strengthening their research and collaboration in the NCD field and will be launching a pilot study in August on conducting longitudinal studies of risk factors for cardiovascular disease in Uganda.   Locally targeted research project To date, some 40 doctoral students from Uganda have graduated through the partnership and joint degree scheme, and over 500 peer-reviewed scientific articles have been published. It is hoped that the enlarged pool of researchers and locally targeted research on health issues and healthcare systems will have an impact on the development of Ugandan civil society. In many cases, the outcome has been policy reforms and  changes in practice. More than 300 students and teachers from KI and Makerere University have been on exchange at a Bachelor’s and Master’s level at each university, and strong research capacity has been built in both countries over the years. There are now many alumni from the partnership, and both universities consider them a group worth taking better care of.

High-sensitivity troponin test reduces risk of future heart attack

Tue, 05/06/2018 - 09:48
The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more myocardial infarction patients than before. A new study from Karolinska Institutet published in The Journal of the American College of Cardiology now reports that the risk of a future heart attack is lower in patients diagnosed with the new test. A blood test that measures the presence of heart-specific proteins called troponins is used by emergency clinics to diagnose myocardial infarction in patients with chest pain. For the past few years a newer laboratory method has been used at most hospitals in Sweden that is ten times more sensitive than the conventional troponin test. The high-sensitivity troponin test can discover heart attacks earlier so that treatment can commence, which is thought to improve the patients’ prognosis. “But there is a lack of larger studies examining whether the high-sensitivity troponin test is of any significance for patients with newly diagnosed myocardial infarction in terms of survival or the risk of another heart attack,” says study leader Dr Martin Holzmann, associate professor of epidemiology at Karolinska Institutet’s Department of Medicine in Solna and physician at Karolinska University Hospital. Fewer new heart attacks The study included all patients in Sweden who had had their first heart attack between 2009 and 2013. This gave a study population of almost 88,000 patients, 40,000 of whom had been diagnosed using the high-sensitivity troponin test and just over 47,000 using the conventional troponin test. The researchers found that five per cent more myocardial infarctions were being diagnosed in hospitals that used the high-sensitivity troponin test. A year after the heart attack was registered there was no difference in mortality between the two groups, although the number of new heart attacks was lower in the group that had been diagnosed using the high-sensitivity troponin test. “This surprised us,” says Dr Holzmann. “We didn’t think that the more sensitive test would affect the risk of future heart attacks.” Better risk assessment The use of coronary angiography and balloon angioplasty was 16 and 13 per cent more common, respectively in the patients diagnosed with the high-sensitivity troponin test. In the USA, where the new test was not approved until 2017, there are fears that the more sensitive methods can entail a large increase in the number of examinations with no benefit to the patients. “The increase we observed in our study was less than expected, which means that the high-sensitivity troponin test has enabled doctors to single out the patients who benefit from such intervention. We found no differences in medication between the two groups, so the differences in prognosis with fewer new heart attacks could be attributed to the fact that more coronary angiography and balloon dilation procedures have been performed on the right patients,” says Dr Holzmann, who also believes that the study supports the idea that the handful of hospitals in Sweden that still do not use the high-sensitivity troponin test should start to do so. The study was conducted in association with the Sahlgrenska Academy and Uppsala University. Martin Holzmann receives a grant from the Swedish Heart and Lung Foundation. Per-Ola Andersson has received a lecture fee from pharmaceutical companies Roche, Gilead and Janssen and a consultancy fee from AbbVie, CTI Bipharma and Glaxo-Smith-Kline. Kai M. Eggers has received a consultancy fee from pharmaceutical company Abbott Laboratories, AstraZeneca and Fiomi Diagnostics. Martin Holzmann has received a consultancy fee from pharmaceutical companies Actelion and Pfizer. No other potential conflicts of interest have been reported. Text: Inna Sevelius Publication “High-Sensitivity Troponins and Outcomes After Myocardial Infarction” Maria Odqvist, Per-Ola Andersson, Hans Tygesen, Kai M. Eggers, Martin J. Holzmann Journal of the American College of Cardiology (JACC), online 4 June 2018, doi: 10.1016/j.jacc.2018.03.515

Lipid molecules can be used for cancer growth

Thu, 31/05/2018 - 17:01
Cancer cells can when the blood supply is low use lipid molecules as fuel instead of blood glucose. This has been shown in animal tumour models by researchers at Karolinska Institutet in Sweden in a study published in Cell Metabolism. The mechanism may help explain why tumours often develop resistance to cancer drugs that inhibit the formation of blood vessels. Tumour growth and spread rely on angiogenesis, a process of growing new blood vessels that supply the cancer cells with nutrients and hormones, including glucose (sugar). Treatment with antiangiogenic drugs reduces the number of blood vessels in the tumour as well as the blood glucose supply. Many such drugs have been developed and are now used in human patients for treating various cancer types. However, the clinical benefits of antiangiogenic drugs in cancer patients are generally low and the cancers treated often develop a resistance to drugs, especially cancer types that grow close to fat tissues such as breast cancer, pancreatic cancer, liver cancer and prostate cancers. A new mechanism discovered In collaboration with Japanese and Chinese scientists, a research group at Karolinska Institutet in Sweden has discovered a new mechanism by which cancers can evade antiangiogenic treatment and become resistant. The reduction of tumour blood vessels results in low oxygenation in tumour tissues – a process called hypoxia. In the current study, the researchers show that hypoxia acts as a trigger to tell fat cells surrounding or within tumour tissues to break down the stored excessive lipid energy molecules. These lipid energy molecules can when the blood supply is low be used for cancer tissue expansion. “Based on this mechanism, we propose that a combination therapy consisting of antiangiogenic drugs and drugs blocking lipid energy pathways would be more effective for treating cancers. In animal tumour models, we have validated this very important concept, showing that combination therapy is superior to monotherapy,” says Yihai Cao, Professor at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet, who led the study. Explore combination therapy effects Professor Cao’s group now plans to work with drug companies and clinical oncologists to explore whether such a new combination therapy would improve the quality of life and lifespan in human cancer patients. The study was financed by the Swedish Research Council, the Swedish Cancer Foundation, Karolinska Institutet, the Torsten Söderberg Foundation, the Tore Nilson Foundation, the Ruth and Richard Julin Foundation, the Ögonfonden Foundation, the Wera Ekström Foundation, the Lars Hierta Memorial Foundation, National Natural Science Foundation of China, the International Research Fund for Subsidy of Kyushu University School of Medicine Alumni, the Martin Rind Foundation, the Maud and Birger Foundation, the Alex and Eva Wallström Foundation, the Robert Lundberg Memorial Foundation, the Swedish Diabetes Foundation, the Swedish Childhood Cancer Fund, the European Research Council, the Knut and Alice Wallenberg Foundation, and the Novo Nordisk Foundation. Publication “Cancer lipid metabolism confers antiangiogenic drug resistance” Hideki Iwamoto, Mitsuhiko Abe, Yunlong Yang, Dongmei Cui, Takahiro Seki, Masaki Nakamura, Kayoko Hosaka, Sharon Lim, Jieyu Wu, Xingkang He, Xiaoting Sun, Yongtian Lu, Qingjun Zhou, Weiyun Shi, Takuji Torimura, Guohui Nie, Qi Li, and Yihai Cao. Cell Metabolism, online 31 May 2018, doi: 10.1016/j.cmet.2018.05.005

Inefficient fat metabolism a possible cause of overweight

Thu, 31/05/2018 - 17:01
Protracted weight gain can, in some cases, be attributed to a reduced ability to metabolise fat, a new study from Karolinska Institutet published in the esteemed journal Cell Metabolism shows. Sensitive individuals might need more intensive lifestyle changes if they are to avoid becoming overweight and developing type 2 diabetes, claim the researchers, who are now developing means of measuring the ability to break down fat. Scientists have long sought an explanation for variations in the tendency for people to develop overweight, obesity and type 2 diabetes. Apart from lifestyle factors, such as diet and physical activity, physiological differences in metabolism – which would eventually lead to differences in weight gain amongst people – is suspected to play a part.  “We’ve suspected the presence of physiological mechanisms in fatty tissue that cause some people to become overweight and others not, despite similarities in lifestyle, and now we’ve found one,” says Mikael Rydén, professor of clinical and experimental fat tissue research at Karolinska Institutet’s Department of Medicine in Huddinge.  Analysed tissue samples  In the present study, the researchers analysed tissue samples from subcutaneous fat taken from the stomachs of women before and after a follow-up period of about ten years. What they discovered was that the ability of the fat cells to free fatty acids, a process called lipolysis, in the first tissue sample could be used to predict which women would have developed type 2 diabetes by the end of the study. They also found that these women had reduced activity in a small number of specific genes involved in lipolysis. Lipolysis is the process whereby a fat cell frees fatty acids, which are then used as a source of energy by the muscles. Researchers differentiate between basal lipolysis, which is continual, and hormone-stimulated lipolysis, which is triggered in response to an increase in energy requirement. The fat cells from the women who later developed overweight showed high basal but low hormone-stimulated lipolysis, which gave a 3 to 6 times higher risk of weight gain and type 2 diabetes.  “It’s a bit like a car that’s at high revs but that’s lost its ability to get into gear when it needs to,” says Professor Rydén. “The end result is that the fat cells eventually take up more fat than they can get rid of.”  New method The teams first discovered the correlation in a group of 54 women, who gave the first tissue samples between 2001 and 2003 and who were followed up 13 years later. They then repeated the analysis on 28 other women who gave samples in 1998 and were followed up ten years later, with the same results.  One of the researchers’ aims is to find ways of identifying individuals who run the risk of developing overweight and type 2 diabetes. Analyses of fat tissue are, however, relatively resource-demanding and can only be performed by specially equipped laboratories. Consequently, the researchers have developed an algorithm based on simple clinical and biochemical parameters from hundreds of individuals in order to obtain an indirect estimation of the quantity of fatty acids freed by the fat cells and thus predict weight gain. “Our results now need to be corroborated in larger studies and for men as well, but we hope to develop a clinically expedient way of identifying individuals at risk of developing overweight and type 2 diabetes, who might need more intensive lifestyle intervention than others to stay healthy,” says Professor Rydén. The study was financed by the Swedish Research Council, the Novo Nordisk Foundation, the Swedish Diabetes Foundation, the European Foundation for the Study of Diabetes, Stockholm County Council and Karolinska Institutet. Genetic analyses were performed with grants from CLARINS, 92200 Neuilly sur Seine. Publication  “Weight gain and impaired glucose metabolism in women is predicted by inefficient subcutaneous fat cell lipolysis” Peter Arner, Daniel P. Andersson, Jesper Bäckdahl, Ingrid Dahlman and Mikael Rydén Cell Metabolism, online 31 May 2018, doi: 10.1016/j.cmet.2018.05.004

Hans Möller appointed new CEO of Karolinska Institutet Holding AB

Thu, 31/05/2018 - 11:23
Karolinska Institutet Holding AB has recruited Hans Möller as the new CEO for the KI Holding Group. Hans Möller will assume his new position as of July 16. He is presently holding the position as responsible for the Edinburgh BioQuarter at the University of Edinburgh.  Hans has extensive experience of working in the interface between academy and industry, including as CEO for Ideon Science Park in Lund and as a founder of Ideonfonden and the incubator Ideon Innovation. Hans acted until April 2018 as chairman of the board for KI Science Park AB. – Hans´ experience and knowledge of how to create good conditions and platforms to explore outcomes of research and education, are extremely valuable, says Karin Dahlman-Wright, Chairman of the Board for KI Holding. – I very much look forward to leading KI Holding into the future. The possibilities and challenges to create the right conditions, to support innovations within Life Science are many. Sweden in general and KI in particular, has a special position when it comes to world leading research in Life Science, says Hans Möller.

Anti-inflammatory strategy stops aggressive childhood cancer

Mon, 28/05/2018 - 16:09
Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumour stroma reduces tumour growth in experimental neuroblastoma models. The findings are published in EBioMedicine and open for new treatment strategies for this aggressive childhood cancer. “High-risk neuroblastoma is the most common and deadly cancer in infants. Novel therapies are highly warranted, in particular if they improve survival without adding adverse side effects,” says Professor Per Kogner at Karolinska Institutet’s Department of Women’s and Children’s Health, who led the study together with Professor Per-Johan Jakobsson at Karolinska Institutet’s Department of Medicine, Solna. Neuroblastoma is an aggressive nerve cell tumour which is diagnosed early, often before two years of age, and is stratified into different risk categories: low-risk, intermediate-risk and high-risk. Children with high-risk neuroblastoma receive intensive multi-modal treatment that has increased survival over the years but survivors both have high risk of life-threatening relapse and severe life-long side effects. Targeting of the stromal compartment has been suggested as a new strategy to increase survival further and to increase the quality of life of children who survive the disease. Targeting benign cells “We found that the dominant cell type in the tumour stroma, benign cancer-associated fibroblasts, were the main producers of prostaglandin E2 in neuroblastoma,” says Anna Kock, PhD at the Department of Women’s and Children’s Health and first author of the study. “These normal cells support the growth of cancer cells and should be targeted since they are more genetically stable than the malignant cells, and therefore less prone to develop resistance.” Assistant professor Karin Larsson at the Department of Medicine, Solna, who has worked on the project for several years, explains: “Prostaglandin E2 not only mediates fever and pain, but also drives inflammation in the tumours, promoting tumour growth. Inhibition of the enzyme mPGES-1, that catalyses the production of prostaglandin E2, resulted in reduced tumour growth in experimental neuroblastoma models.” The researchers believe that the finding could lead to improved survival with fewer side effects for children with neuroblastoma. Begin to understand the mechanisms ”mPGES-1 is an emerging target for treatment of inflammation and pain with cardioprotective properties. NSAIDs, which result in reduced prostaglandin levels, have long been implicated as prophylaxis against certain cancers. Our present study pinpoints mPGES-1 in neuroblastoma and we now begin to understand the mechanisms behind its involvement in cancer growth,” says Professor Per-Johan Jakobsson, who discovered mPGES-1. The work was financed by the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, The Cancer Research Funds of Radiumhemmet, the Swedish Foundation for Strategic Research, the Swedish Rheumatism Association and grants from the EU’s seventh framework program. Publication “Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth” Anna Kock, Karin Larsson, Filip Bergqvist, Nina Eissler, Lotta H.M. Elfman, Joan Raouf, Marina Korotkova, John Inge Johnsen, Per-Johan Jakobsson, Per Kogner EBioMedicine, online 24 May 2018, doi: 10.1016/j.ebiom.2018.05.008

“Neo – a fine example of democracy”

Mon, 28/05/2018 - 10:41
Transparency is the word that best describes Neo, Karolinska Institutet’s new research facility in Flemingsberg, which saw its official opening on 25 May.  The ribbon was cut by Princess Christina, Mrs Magnuson. Neo is a vital part of the Life Science cluster that puts the Flemingsberg campus on the map of world-leading research. “This building is a fine example of democracy,” says Karolinska Institute president Ole Petter Ottersen. “What makes Neo unique is that it’s open access, creating fantastic opportunities and enabling unbeatable interactions. Neo symbolises transparency and collaboration. With so many people of different nationalities and backgrounds, something magical is bound to happen.” Professor Ottersen officially opened Neo in the company of Princess Christina, Mrs Magnuson, honorary doctor of medicine at Karolinska Institutet.  “Officiating at the opening of Neo means so many things to me,” she said. “I was involved in KI’s second-centenary celebrations and made sure that we raised superb proceeds for research. It was my way of saying thank you for the honorary doctorate.”  She went on to talk about the many illnesses she has had in the course of her life, and how grateful she feels to be healthy again.  “I’ve got a feeling that something amazing is happening here at Neo, it’s like a global microcosmos, with all the researchers from at least thirty countries bringing all sorts of experience. It’s a fantastic crucible of knowledge.”  Room for 400 researchers Neo covers an area of 15,000 square metres, with space for around 400 researchers on seven floors. Five thousand square metres consists of laboratory space. Here can be found four of KI’s departments represented:  The Department of Biosciences and Nutrition. The Department of Medicine, Huddinge. The Department of Neurobiology, Care Sciences and Society. The Department of Laboratory Medicine. During the opening ceremony, participants were able to attend a number of scientific mini-symposia on different themes, such as Alzheimer’s and diabetes research.  An atrium exploding with colour The ground floor of Neo boasts the brilliantly coloured atrium with its eye-catching spiral staircase shaped like DNA spirals. Next to the atrium are two spherical auditoriums built from translucent concrete (butong) modules. The surface is like bubble-wrap. “The new feels newer and more complete when juxtaposed with something broken,” says architect Laila Ifwer Sternhoff at Link Arkitektur. “This is why we’ve used translucent concrete to create a sense of weight and antithesis against the new.” The architects have designed the building along the motifs of “new”, “modern” and “germination”. The sound in the auditoriums is intended to facilitate group work, for example, and the rooms are everyone’s – the departments have access to all parts of the building. “In Neo, we’ve created a positive work environment with no distinct boundaries between departments and research groups,” says Karl Ekwall, head of the Department of Biosciences and Nutrition. According to Jan Bolinder, head of the Department of Medicine, there has always been an open mind here as regards interdisciplinary scientific collaboration. “I’m convinced that this spirit will flourish even more at Neo with its mix of research groups from different departments,” he says. Maria Eriksdotter, head of the Department of Neurobiology, Care Sciences and Society: “The combination of strong experimental and clinical research in these outstanding new premises, combined with the physical proximity to the hospital and other universities gives us every opportunity to strengthen our already successful research.”   


1 2 3 4 5 6 7 8 9 next › last »